Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen people ask about the good side effects of Mounjaro, they're usually talking about changes beyond the scales — reduced hunger, quieter cravings, and shifts in how food feels. These aren't marketing claims; they're patterns reported consistently in clinical trials and by people on treatment. Mounjaro (tirzepatide) is a prescription-only medicine, and every person's experience is shaped by their own biology, starting dose, and how closely treatment is supervised. The sections below cover what the evidence actually shows, what tends to happen as doses increase, and (just as important) when to take a symptom seriously rather than wait it out.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The change most people notice first is not weight loss itself but a shift in appetite. Tirzepatide activates both GIP and GLP-1 receptors, slowing gastric emptying and signalling fullness to the brain. This dual action is what separates Mounjaro from single-pathway medicines, and it is why clinical trial participants reported meaningful changes in hunger and portion size even at the starter dose, well before reaching higher therapeutic levels.
In SURMOUNT-1, a 72-week trial in adults with obesity, participants at the 15 mg dose achieved an average body-weight reduction of around 20–21%, figures reported in the New England Journal of Medicine. The appetite effect that drove those numbers started earlier. Many people describe meal portions feeling satisfying at sizes that previously left them still hungry, and a quieter internal pull toward snacking. For the majority, this feels like relief rather than restriction.
It is worth understanding that the 2.5 mg starting dose exists primarily to let your system adjust; appetite changes at that stage are variable. The fuller effect tends to build through titration. Your prescriber sets the pace of that titration based on how you are responding, it is not a timeline to rush.
If you want to read more about how tirzepatide works at a clinical level, the NHS tirzepatide page explains the mechanism in patient-friendly language.
Beyond simple appetite reduction, a proportion of people on GLP-1 and dual-agonist medicines report something subtler: less preoccupation with food between meals, reduced urgency around particular cravings, and a shift in how rewarding high-calorie foods feel. This is an area of active research rather than a fully mapped mechanism, but it is consistent enough in trial and observational data to be worth discussing honestly.
Some people also notice improvements in energy levels as weight reduces and metabolic markers improve, blood pressure, blood glucose, and lipid profiles often shift in a positive direction alongside body-weight changes. These secondary changes are not guaranteed, and they are not the primary reason Mounjaro is prescribed, but they are part of why the NICE appraisal of tirzepatide (TA1026) described its clinical value as extending beyond weight loss alone.
A note on mood: some people report improved mood and confidence as weight changes and energy rises. Separately, there are reports of low mood on GLP-1 medicines in some individuals. Our page on Mounjaro and mood side effects covers what is known and what to watch for, it is worth reading before you start, not after.
The changes in food relationships described above can also interact with established eating patterns. If you have a history of disordered eating, this is something to raise explicitly with your prescriber before treatment begins.
Nausea, loose stools, constipation, indigestion, and fatigue are the most commonly reported unwanted effects. They are not universal, and for many people they are mild and short-lived, peaking shortly after a dose increase then fading. The full side-effect picture is covered in detail on our Mounjaro side effects page; what matters here is the practical balance.
The routine detail that helps most: keeping your pen in the fridge door and injecting on the same day each week creates a rhythm that reduces the chance of a missed or doubled dose, both of which can worsen GI effects. Staying well hydrated and eating smaller, lower-fat meals at the start of each dose level also makes a material difference to tolerability.
There is no version of this medicine without any side effects for every person. What a good prescriber does is help you weigh the benefits against what you are actually experiencing, adjust the titration pace where needed, and distinguish manageable effects from ones that warrant clinical attention. Our page on managing no-side-effect expectations is honest about that trade-off.
For a broader look at tirzepatide's effect profile across the clinical evidence, our page on the good side effects some people experience with tirzepatide is also worth reading alongside the cautions, so you have a complete picture rather than a one-sided one. For a focused look at the most clinically significant unwanted effects, our guide to the five Mounjaro side effects people most commonly ask about covers each one with practical context. Beyond those, less-discussed effects like dry mouth are also documented, worth knowing so nothing catches you off guard.
Most side effects on Mounjaro are gastrointestinal and resolve without intervention. Some require prompt attention. Seek urgent medical help if you experience severe, persistent stomach pain that radiates to the back (with or without vomiting) as this can be a sign of acute pancreatitis, a known but uncommon effect that the MHRA Drug Safety Update (January 2026) highlighted specifically for GLP-1 medicines. Similarly, get medical help promptly for signs of an allergic reaction, symptoms of gallbladder problems (sharp upper-right abdominal pain, fever, jaundice), or significant dehydration from severe vomiting or diarrhoea.
If you notice persistent low mood or any thoughts of self-harm while on treatment, contact your prescriber or GP the same day. These are not side effects to monitor quietly.
Any suspected side effect (including ones you consider minor or unusual) can be reported directly through the MHRA's Yellow Card scheme. Reporting matters: it is how patterns are identified across large populations and how the post-market safety picture for newer medicines like Mounjaro gets clearer over time. Patient reports carry real weight in the MHRA's ongoing monitoring of Black Triangle medicines.
If you are unsure whether something you are experiencing is related to treatment, our aftercare team is available seven days a week, that access is built into every treatment at nume... at every treatment through our pharmacy, not offered as an optional add-on.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.